Alveolar Macrophage Proteomics in HIV-associated Emphysema (HIVE)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Ohio State University.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
Philip Diaz, The Ohio State University Identifier:
First received: January 15, 2009
Last updated: October 24, 2012
Last verified: October 2012

This study is being done to examine lung function changes in individuals with HIV infection and to understand why individuals with HIV have increased risk of lung damage from cigarette smoking.

HIV Infections

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Alveolar Macrophage Proteomics in HIV-associated Emphysema

Resource links provided by NLM:

Further study details as provided by Ohio State University:

Biospecimen Retention:   Samples With DNA

blood lung fluid (optional)

Enrollment: 365
Study Start Date: March 2006
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
HIV smokers with emphysema
HIV smokers without emphysema

Detailed Description:

To delineate the natural history of HIV associated emphysema in the HAART era. To compare the alveolar macrophage proteomes from HIV-seropositive smokers with emphysema to the alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.

To establish whether coinfection with HIV and Hepatitis C results in accelerated lung disease manifested by decrements in forced expiratory volume and carbon monoxide diffusing capacity.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

community sample


Inclusion Criteria:

  • Clinically stable HIV-seropositive (and HIV-seronegative) individuals
  • Ages 18 years and older
  • Female subjects on no oral contraception with a negative pregnancy test
  • Subjects capable of giving written consent

Exclusion Criteria:

  • Known medical illness that would preclude bronchoscopy/BAL (e.g. unstable angina, new cardiac arrhythmia). This only pertains to subjects involved in the bronchoscopy phase of the study.
  • Pregnant females
  • Prisoners
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00823927

United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43026
Sponsors and Collaborators
Philip Diaz
Principal Investigator: Philip T Diaz, MD Ohio State University
  More Information

No publications provided

Responsible Party: Philip Diaz, MD, The Ohio State University Identifier: NCT00823927     History of Changes
Other Study ID Numbers: 2005H0197
Study First Received: January 15, 2009
Last Updated: October 24, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Ohio State University:
lung damage
cigarette smoking

Additional relevant MeSH terms:
Pulmonary Emphysema
Lung Diseases
Lung Diseases, Obstructive
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases processed this record on April 16, 2015